5/12/2022

speaker
Operator
Conference Operator

Good day and thank you for standing by. Welcome to the first quarter 2022 Solaris Pharmaceuticals Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require assistance during the conference, please press star zero. I would now like to hand the conference over to your speaker today, Daniel Canto-Boateng.

speaker
Daniel Canto-Boateng
Investor Relations

Good afternoon, and thank you for joining Solaris Pharmaceuticals' 2022 First Quarter Financial and Corporate Results Call. This afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months ended March 31, 2022, which we encourage listeners to read. The press release can be found in the news section of solarisfarma.com. Before beginning today's call, I would like to make the following statement. Today, we will be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, the development and effectiveness of our investigational drug candidates, Secodemstat, and SP3164, as well as our targeted protein degradation program and expectations regarding our capital allocation and cash resources, as well as asking shareholders to vote before or during the 2022 Annual Stockholders Meeting taking place on June 15, 2022. These statements are based on our current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risk and uncertainties, including those detailed in the Risk Factors section of Solaris Pharmaceuticals Annual Report on Form 10-K for the year ended 2021. and subsequent quarterly reports on Form 10Q, which have been filed with the SEC, as well as other filings we make with the SEC from time to time. Solaris Pharmaceuticals disclaims any obligation to update information contained in these four looking statements, whether as a result of new information, future events, or otherwise. With us on today's call is David Arthur, Director and CEO of Solaris Pharmaceuticals, who will provide an update on Solaris' corporate and clinical achievements during the first quarter and its vision for the future, and Mark Rosenblum, CFO, who will review Solaris' first quarter financial results. David, please go ahead.

speaker
David Arthur
Director and CEO

Thank you, Daniel, and thank you to everyone dialing into our conference call today, particularly all of you joining us for the first time. The first quarter of 2022 and recent weeks have once again been another exciting time for Solaris. The highlight of the quarter was our acquisition of an intellectual property portfolio from Duterex LLC, led by the drug candidate SP3164. 3164 now forms the basis of our Targeted Protein Degradation, or TPD, drug development program. And although we spoke recently on March 10th during our 2021 year-end earnings call, We already have news on advancing our 3164 drug development program, which I'll discuss in a moment. Our entry into protein degradation represents a significant expansion of our internal drug development pipeline, and we believe positions Solaris for significant future growth. TPD is a fast-growing field of cancer drug research with a commercial market potential in the billions of dollars as evidenced by drugs like Revlimid and Pomelis. that in 2021 generated global sales of over $16 billion, as reported by Bristol-Myers Squibb in their fourth quarter and full-year financial results for 2021. In addition, the potential market for TPD is attracting interest from some of the world's largest drug makers, including Bristol-Myers Squibb, Amgen, Pfizer, Novartis, and others who have recently announced deals with biotechnology companies that are focused on targeted protein degradation. We believe that the investment by pharma in protein degradation suggests the potential for protein degradation to be transformative within the healthcare space. Coupled with our existing clinical development program for seclidemstat, an oral reversible LSD1 inhibitor, and our most advanced investigational cancer drug candidate, Solaris is now pursuing multiple drug development programs built around two exciting approaches to targeted cancer drug development, protein inhibition and protein degradation. We are optimistic of the future given the multiple milestones we expect to soon achieve and the potential to deliver value inflection points for our shareholders. As CEO and a shareholder in the company, I'm as excited about our future as I have been since arriving at Solaris. Let me tell you about what we see ahead for the future of Solaris, and I'd like to start with seclodemstat. As you know, seclodemstat is an oral reversible protein inhibitor designed to target LSD1, an enzyme that is overexpressed in many types of cancer, and an enzyme that is a promising target for anti-cancer drug therapies. And as you also know, Ceclodemstat is currently the subject of two separate Phase I-II clinical trials. The first trial is exploring its potential in sarcomas, including one treatment arm exploring Ceclodemstat in combination with chemotherapy for patients with Ewing sarcoma. The second trial is an investigator-initiated trial sponsored by MD Anderson Cancer Center in Houston, exploring Ceclodemstat's potential in patients with two aggressive forms of hematologic or blood cancers. Ceclodemstack continues to advance in clinical development with patients enrolling across both clinical trials, and as we have discussed previously, we are looking forward to providing updates on these studies, including interim clinical data later this year. Now, let's discuss SP3164 and targeted protein degradations. Targeted protein degradation involves harnessing the body's natural degradation system to selectively target and eliminate disease-causing proteins, and by doing so, stop the development and progression of cancer. This field of research has helped to transform the treatment of cancer with products such as Revlimid and Pommelast, as I mentioned earlier. Both drugs are protein degraders indicated for the treatment of blood malignancies such as multiple myeloma and non-Hodgkin lymphoma. We believe that the therapeutic success of these early generations of protein degraders represents significant potential for protein degradation to enable the development of medicines that can achieve a therapeutic effect with small quantities of drugs. But perhaps the most exciting part about targeted protein degradation is the potential to develop medicines that target cancer-promoting proteins that have historically been considered undruggable. We have observed the broader biopharmaceutical industry's interest in targeted protein degradation through a number of transactions over the past two years. We believe in 3164, and we believe in its potential to be best in class. 3164 is an oral small molecule cereblon binding protein degrader referred to as a molecular glue because it is designed to bring disease-causing proteins into proximity with an enzyme that induces the disease-causing proteins elimination or degradation. What we think makes 3164 unique is that it is the preferred half or preferred enantiomer of the widely studied drug avatamide with the potential for increased efficacy and improved safety. Based on published reports, avatamide, or cell gene CC122, has been studied in more than 400 patients across 10 clinical trials, demonstrating a promising safety profile, good pharmacokinetics, and importantly, anti-tumor activity across several cancer types with what we believe is strong data in lymphomas. This is important because 3164, though derived from avatamide, is actually a new molecular entity with unique and improved characteristics and its own composition of matter pattern. In fact, in a preclinical animal study, where results were published in the proceedings of the National Academy of Sciences, 3164 showed improved efficacy and increased anti-tumor activity in multiple myeloma compared to Avatamide. Solaris is focused on advancing 3164 into the clinic as quickly as possible as a potential treatment for hematologic cancers and solid tumors. And we are pleased to announce, in fact, we announced yesterday afternoon that we have completed the pre-investigational new drug or pre-IND meeting process with the FDA. The pre-IND meeting process allows companies to submit drug development questions to the FDA and receive guidance to inform studies and development activities to prepare an IND application. Solaris has completed this important drug development step and obtained valuable FDA input that provided clarity on preclinical clinical, and other regulatory matters for preparing and submitting an IND. Solaris is actively implementing IND-enabling studies and other development activities to support a planned IND submission in the first half of 2023. Importantly, we plan to provide preclinical data updates later this year. The progress we have seen so far in our 3164 development program gives us confidence that we will be able to initiate our first 3164 clinical trial in 2023, next year. As I mentioned earlier, and hopefully as you can now appreciate, it's been another exciting quarter in recent weeks here at Solaris. And our annual stockholder meeting is next month. But before I discuss our upcoming stockholder meeting, I would like to ask Mark Rosenblum, Chief Financial Officer, to provide details on our first quarter financial results. Mark?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-